Literature DB >> 12847115

Disparate roles of AT2 receptors in the renal cortical and medullary circulations of anesthetized rabbits.

Lisa M Duke1, Gabriela A Eppel, Robert E Widdop, Roger G Evans.   

Abstract

The contributions of angiotensin II type 1 (AT1) and type 2 (AT2) receptors to the control of regional kidney blood flow were determined in pentobarbital-anesthetized rabbits. Intravenous candesartan (AT1 antagonist; 10 microg/kg plus 10 microg x kg(-1) x h(-1)) reduced mean arterial pressure (12%) and increased total renal blood flow (29%) and cortical laser-Doppler flux (18%) but not medullary laser-Doppler flux. Neither intravenous PD123319 (AT2 antagonist; 1 mg/kg plus 1 mg x kg(-1) x h(-1)) nor saline vehicle significantly affected these variables, and the responses to candesartan plus PD123319 were indistinguishable from those of candesartan alone. In vehicle-treated rabbits, renal-arterial infusions of angiotensin II (1 to 25 ng x kg(-1) x min(-1)) and angiotensin III (5 to 125 ng x kg(-1) x min(-1)) dose-dependently reduced renal blood flow (up to 51%) and cortical laser-Doppler flux (up to 50%) but did not significantly affect medullary laser-Doppler flux or arterial pressure. Angiotensin(1-7) (20 to 500 ng x kg(-1) x min(-1)) had similar effects but of lesser magnitude. CGP42112A (20 to 500 ng x kg(-1) x min(-1)) did not significantly affect these variables. After PD123319 administration, angiotensin II and angiotensin III dose-dependently increased medullary laser-Doppler flux (up to 84%), and reductions in renal blood flow in response to angiotensin II were enhanced. Candesartan abolished renal hemodynamic responses to the angiotensin peptides, even when given in combination with PD123319. We conclude that AT2 receptor activation counteracts AT1-mediated vasoconstriction in the renal cortex but also counteracts AT1-mediated vasodilatation in vascular elements controlling medullary perfusion. These mechanisms might have an important effect on the control of medullary perfusion under conditions of activation of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847115     DOI: 10.1161/01.HYP.0000083341.64034.00

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

2.  Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase.

Authors:  S M Chajkowski; J Mallela; D E Watson; J Wang; C R McCurdy; J M Rimoldi; Z Shariat-Madar
Journal:  Biochem Biophys Res Commun       Date:  2010-12-16       Impact factor: 3.575

3.  AT(2) receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension.

Authors:  Lisa M Duke; Robert E Widdop; Michelle M Kett; Roger G Evans
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats.

Authors:  Samira Choopani; Mehdi Nematbakhsh
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-07-01       Impact factor: 4.109

Review 5.  Vascular angiotensin II actions mediated by angiotensin II type 2 receptors.

Authors:  Ruth E Hannan; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

6.  High-Dose Estradiol-Replacement Therapy Enhances the Renal Vascular Response to Angiotensin II via an AT2-Receptor Dependent Mechanism.

Authors:  Tahereh Safari; Mehdi Nematbakhsh; Roger G Evans; Kate M Denton
Journal:  Adv Pharmacol Sci       Date:  2015-11-23

Review 7.  AT2 receptors: functional relevance in cardiovascular disease.

Authors:  Emma S Jones; Antony Vinh; Claudia A McCarthy; Tracey A Gaspari; Robert E Widdop
Journal:  Pharmacol Ther       Date:  2008-08-31       Impact factor: 12.310

8.  Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.

Authors:  Eugenie Shieh; Mark A Marzinke; Edward J Fuchs; Allyson Hamlin; Rahul Bakshi; Wutyi Aung; Jennifer Breakey; Tonia Poteat; Todd Brown; Namandjé N Bumpus; Craig W Hendrix
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.